KdT Ventures
Edit

KdT Ventures

https://www.kdtvc.com
Last activity: 19.06.2025
Active
Invests in categories: PlatformHealthTechMaterialsTechnologyProductBioTechMedTechDrugEngineeringArtificial Intelligence
KdT Ventures is the standard for early-stage frontier science investing.
Portfolio
52
Persons
8
Mentions
23
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A; Series B
.

Portfolio 52

DateNameWebsiteTotal RaisedLocation
19.06.2025Creasalliscreasallis.com--
19.06.2025MacroCycle...macrocycle.tech$6.5MUnited Sta...
19.06.2025Exthymic C...exthymic.com--
19.06.2025Epana Bioepana.bio--
19.06.2025Reverb The...reverbtx.com$12M-
19.06.2025Index Bios...indexbiosystems.com-Canada, On...
19.06.2025PHNX Mater...phnxmaterials.com--
02.12.2024March Biomarch.bio$33.2M-
10.01.2024Perceptiveperceptive.io-United Sta...
19.07.2023SURGE Ther...surgetx.com$58M-
Show more

Persons 8

DateFirst NameLast NameTitleLinkedInLocation
-KetanYerneniPrincipallinkedin.c...-
-PhilGrayeskiPartnerlinkedin.c...-
-YusufUddin, PhDHead of Ta...linkedin.c...-
-BlairWilletteSenior Fel...linkedin.c...-
-MackHealyPartnerlinkedin.c...-
-RimaChakrabart...Partnerlinkedin.c...-
-CainMcClary, M...Founder an...linkedin.c...-
-PatrickMalone, MD...Principallinkedin.c...-

Mentions in press and media 23

DateTitleDescription
06.02.2025MacroCycle Raises $6.5M to Commercialize Plastic Upcycling Technology with 80% Less EnergyBacked by U.S. and European investors, MacroCycle is enabling a circular plastics supply chain beginning with PET bottles and polyester textile waste MacroCycle Technologies, a developer of a novel PET & polyester textile waste upcyclin...
17.10.2024KdT Ventures Closes Fourth Fund, at over $100MKdT Ventures, an Austin, Texas-based venture capital firm backing frontier science companies, closed its fourth fund, at over $100m. The fund, the firm’s largest fund to date, follows KdT’s previous $80 million Fund III which was announced ...
26.01.2024Motif Neurotech Raises $18.75M for Implantable Device for Treatment-Resistant DepressionWhat You Should Know: – Motif Neurotech, a pioneer in minimally-invasive bioelectronics for mental health, announced today an impressive $18.75 million Series A funding round. Led by Arboretum Ventures, the investment saw participation from...
18.01.2022BREAKING: Faeth raises $20m from Khosla, AgFunder to battle cancer with foodDisclosure: AFN’s parent company, AgFunder, is an investor in Faeth Therapeutics. Faeth Therapeutics, a startup developing precision nutrition solutions to help fight cancer, has raised $20 million in seed funding in a round led by Khosla V...
18.01.2022Faeth raises $20m from Khosla, AgFunder to battle cancer with foodDisclosure: AFN’s parent company, AgFunder, is an investor in Faeth Therapeutics. Faeth Therapeutics, a startup developing precision nutrition solutions to help fight cancer, has raised $20 million in seed funding in a round led by Khosla V...
17.09.2021Debut Biotech is creating next-gen ingredients through ‘cell-free biomanufacturing’With climate change and its environmental consequences upon us, many companies are turning to more ‘natural’ alternatives to the chemical-based ingredients commonly used in food, beverages, cosmetics, and therapeutics. One such company is S...
16.09.202154gene Closes $25M Series B to Advance Global Drug Discovery Capabilities
14.09.2021BREAKING: Nitrogen fixer Andes scores $15m from Bayer, Wilbur-Ellis to move into carbon captureAndes, a Chilean-founded, US-based ag biotech startup, has raised $15 million in Series A funding. The round was co-led by the VC arms of Bayer and Wilbur-Ellis – Leaps by Bayer and Cavallo Ventures. Existing investors Endurance and KdT Ven...
14.09.2021Nitrogen fixer Andes scores $15m from Bayer, Wilbur-Ellis to move into carbon captureAndes, a Chilean-founded, US-based ag biotech startup, has raised $15 million in Series A funding. The round was co-led by the VC arms of Bayer and Wilbur-Ellis – Leaps by Bayer and Cavallo Ventures. Existing investors Endurance and KdT Ven...
12.08.2021Debut Biotech Raises $22.6M Series A to Commercialize High-Value Ingredients from Proprietary Cell-Free Biomanufacturing PlatformBy overcoming the limitations of cell-based fermentation, Debut Biotech produces high-value ingredients rapidly and more sustainably. SAN DIEGO (PRWEB) August 12, 2021 Debut Biotech, a next generation biomanufacturing platform harnessing ce...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In